Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jennifer R. Riggs"'
Autor:
John F. Boylan, Jennifer R. Riggs, Heather K. Raymon, Ning Jiang, Tao Shi, Yuhong Ning, David Mikolon, Tam Tran, Rama Krishna Narla, Leo A. Barnes, Sophie X. Peng, Gordafaried Deyanat-Yazdi, Shuichan Xu, Dan Zhu
Historically, phenotypic-based drug discovery has yielded a high percentage of novel drugs while uncovering new tumor biology. CC-671 was discovered using a phenotypic screen for compounds that preferentially induced apoptosis in triple-negative brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc39d765a5b86cd0bea57f9dd0bcd25
https://doi.org/10.1158/1535-7163.c.6537733
https://doi.org/10.1158/1535-7163.c.6537733
Autor:
John F. Boylan, Jennifer R. Riggs, Heather K. Raymon, Ning Jiang, Tao Shi, Yuhong Ning, David Mikolon, Tam Tran, Rama Krishna Narla, Leo A. Barnes, Sophie X. Peng, Gordafaried Deyanat-Yazdi, Shuichan Xu, Dan Zhu
SUPPLEMENTAL METHODS • Correlative analysis of CC-671 sensitivity data with genomic features in the 240 Oncopanel • Correlative analysis of CC-671 sensitivity data with genomic features or tumor subtypes in 49 breast cancer cell lines â
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345d2d16f0cdc9dbe61ef20d892594b3
https://doi.org/10.1158/1535-7163.22504438.v1
https://doi.org/10.1158/1535-7163.22504438.v1
Autor:
Dan, Zhu, Shuichan, Xu, Gordafaried, Deyanat-Yazdi, Sophie X, Peng, Leo A, Barnes, Rama Krishna, Narla, Tam, Tran, David, Mikolon, Yuhong, Ning, Tao, Shi, Ning, Jiang, Heather K, Raymon, Jennifer R, Riggs, John F, Boylan
Publikováno v:
Molecular cancer therapeutics. 17(8)
Historically, phenotypic-based drug discovery has yielded a high percentage of novel drugs while uncovering new tumor biology. CC-671 was discovered using a phenotypic screen for compounds that preferentially induced apoptosis in triple-negative brea
Publikováno v:
Current Cardiovascular Risk Reports. 11
Purpose of Review Advances in medical therapy have resulted in a growing population of older adults with advanced heart failure. Frailty is a clinical syndrome that increases in prevalence with age and is highly prevalent in patients with heart failu
Publikováno v:
Energy & Fuels. 26:5843-5850
Additive packages are used with aviation kerosenes to achieve performance enhancements, such as higher or lower operating temperatures or increased lubricity. An additive that is used to increase operating temperatures for heat sink applications is t
Publikováno v:
Energy & Fuels. 25:2493-2507
There is a great deal of interest in formulating oxygenated diesel fuels that produce low particulate emissions. The most common oxygenate additives for diesel fuels include the glycol ethers, glycol esters, alcohols, ethers, and ketones. It is impor
Publikováno v:
Energy & Fuels. 24:5611-5623
RP-1 is a long-established hydrocarbon fuel that continues to be widely used as the kerosene component in rocket propulsion systems. The desire in recent years to use rocket motors many times, rather than a single time, has led to reformulations of R
Autor:
Aleksandr Kolesnikov, Ellen Sanford, Dange Vijaykumar, Michael J. Green, Kieron E. Wesson, Jennifer R. Riggs, Paul A. Sprengeler, Troy A. Wahl, Christine Yu, William D. Shrader, Huiyong Hu, Ellen M. Leahy, Wendy B. Young, Zhiwei Tong, Brad A. Katz, Margaret Nguyen, Ronnel Cabuslay
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:3197-3200
The discovery and development of 5-azaindole factor VIIa inhibitors will be described.
Autor:
Michael J. Green, Juthamas Sukbuntherng, John Hendrix, Liang Liu, William D. Shrader, Jennifer R. Riggs, Robin Stephens, Wendy B. Young, Aleksandr Kolesnikov, Dange Vijaykumar, Lin Pan, Joyce Mordenti
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:2224-2228
We have developed a series of potent and selective factor VIIa inhibitors based on the 2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6-hydroxy-biphenyl-3-yl]-succinic acid scaffold. These amidine-containing compounds have low oral bioavailability. Her